• LAST PRICE
    0.0177
  • TODAY'S CHANGE (%)
    Trending Down-0.0009 (-4.9919%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.0178 / 0.0186
  • Day Range
    Low 0.0161
    High 0.0194
  • 52 Week Range
    Low 0.0153
    High 0.0420
  • Volume
    39,183
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 0.01863
TimeVolumeGBLX
09:32 ET49500.0161
09:42 ET10000.0194
09:51 ET8000.01758
10:11 ET270100.0165
10:26 ET2250.01775
11:09 ET15200.01785
12:06 ET20000.01748
12:55 ET5880.016665
02:52 ET5400.017
03:51 ET5000.0177
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesGBLX
GB Sciences Inc
6.7M
-34.7x
---
United StatesQRON
Qrons Inc
6.7M
-7.2x
---
United StatesXTLB
X T L Biopharmaceuticals Ltd
6.8M
-2.3x
---
United StatesREVB
Revelation Biosciences Inc
6.6M
-0.5x
---
United StatesATXI
Avenue Therapeutics Inc
6.6M
-0.4x
---
United StatesHILS
Hillstream BioPharma Inc
6.9M
-1.5x
---
As of 2023-01-29

Company Information

GB Sciences, Inc. is a biopharmaceutical research and development company. The Company develops disease-targeted formulations of cannabis and other plant-inspired therapeutic mixtures for the prescription drug market through its wholly owned subsidiary, GbS Global Biopharma, Inc. (GBSGB). The Company's primary focus is on preparing its lead program for the treatment of the motor symptoms of Parkinson's disease (PD) in a human clinical trial. Through GBSGB, the Company is engaged in the research and development of plant-inspired medicines, with virtual operations in North America and Europe. GBSGB has a portfolio of intellectual property containing both plant-inspired formulations and its artificial intelligence (AI)-enabled drug discovery platform, as well as research contracts and various supplier arrangements. GBSGBs intellectual property covers a range of over 65 medical conditions, from which five drug development programs are in the preclinical stage of drug development.

Contact Information

Headquarters
6450 Cameron St Ste 110ALAS VEGAS, NV, United States 89118-4337
Phone
888-895-3594
Fax
---

Executives

Chairman of the Board, President, Chief Executive Officer
John Poss
President, Chief Science Officer
Andrea Small-Howard
Chief Financial Officer, Treasurer
Zach Swarts
Company Secretary
Gary Henrie
Independent Director
Edmond Defrank

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$6.7M
Revenue (TTM)
$0.00
Shares Outstanding
379.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.56
EPS
$0.00
Book Value
$-0.01
P/E Ratio
-34.7x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
38.4x
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.